XML 49 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Deferred Revenue - Additional Information (Detail)
$ / shares in Units, € in Thousands, $ in Thousands, shares in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 28, 2017
EUR (€)
Feb. 28, 2017
USD ($)
Dec. 20, 2016
EUR (€)
$ / shares
Jan. 31, 2017
USD ($)
Jun. 30, 2019
EUR (€)
shares
Mar. 31, 2019
EUR (€)
Mar. 31, 2019
USD ($)
Jun. 30, 2019
EUR (€)
shares
Jun. 30, 2019
USD ($)
$ / shares
Jun. 30, 2018
EUR (€)
Dec. 31, 2018
USD ($)
Jun. 30, 2019
USD ($)
shares
Dec. 31, 2018
EUR (€)
Dec. 20, 2016
USD ($)
Disclosure of deferred income [line items]                            
Total deferred revenue         € 106,874     € 106,874         € 114,609  
Aggregate purchase price               1   € 44,731        
Revenue recognized         100     200            
Upfront and Milestone Payments [member]                            
Disclosure of deferred income [line items]                            
Revenue recognized         200     500            
Incyte Corporation [member]                            
Disclosure of deferred income [line items]                            
Non-refundable upfront payment receivable         € 112,000     € 112,000       $ 120,000    
Common shares issued | shares         3.2     3.2       3.2    
Purchase price per share | $ / shares                 $ 25.00          
Aggregate purchase price | $       $ 80,000                    
Non-refundable upfront payment € 112,000 $ 120,000                        
Incyte collaboration agreement [member]                            
Disclosure of deferred income [line items]                            
Total deferred revenue         € 104,700     € 104,700         112,600  
Non-refundable upfront payment               112,000 $ 120,000          
Consideration from the issuance and sale of common shares               143,400 152,600          
Simcere collaboration and license agreement [member]                            
Disclosure of deferred income [line items]                            
Total deferred revenue         1,600     1,600         € 2,100  
Non-refundable upfront payment               2,300 2,750          
Milestone payments               600 800          
Betta collaboration and license agreement [member]                            
Disclosure of deferred income [line items]                            
Total deferred revenue         € 600     600            
ONO Research and License Agreement [member]                            
Disclosure of deferred income [line items]                            
Performance obligation recognized as revenue | $                     $ 1,200      
Paid for full time equivalent funding               200            
Compensate for research service               300            
ONO Research and License Agreement [member] | Deferred revenue [member]                            
Disclosure of deferred income [line items]                            
Non-refundable upfront payment               700            
Incyte share subscription agreement [member]                            
Disclosure of deferred income [line items]                            
Total deferred revenue     € 31,400                     $ 32,600
Purchase price per common share | $ / shares     € 25.00                      
Consideration from the issuance and sale of common shares               31,400 32,600          
Betta Pharmaceuticals Co Ltd [member]                            
Disclosure of deferred income [line items]                            
Non-refundable upfront payment           € 900 $ 1,000              
Milestone payments           € 10,500 $ 12,000 € 10,500 $ 12,000